These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 24435057)

  • 1. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
    Saylor PJ
    Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
    Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
    Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone health and prostate cancer.
    Saylor PJ; Smith MR
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
    Saylor PJ; Lee RJ; Smith MR
    J Clin Oncol; 2011 Sep; 29(27):3705-14. PubMed ID: 21860001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and prevention of bone complications from prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of bone metastases in refractory prostate cancer--role of denosumab.
    Paller CJ; Carducci MA; Philips GK
    Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and emerging therapies for bone metastases in genitourinary cancers.
    Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
    Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing bone complications in prostate cancer.
    Bishr M; Saad F
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):299-303. PubMed ID: 22871982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
    Smith MR
    Urol Oncol; 2008; 26(4):420-5. PubMed ID: 18593621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary therapeutic approaches targeting bone complications in prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Clin Genitourin Cancer; 2010 Dec; 8(1):29-36. PubMed ID: 21208853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
    Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
    N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-targeted agents: preventing skeletal complications in prostate cancer.
    Morgans AK; Smith MR
    Urol Clin North Am; 2012 Nov; 39(4):533-46. PubMed ID: 23084529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metastases and bone loss medical treatment in prostate cancer patients.
    Safriadi F
    Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic fracture in patients with metastatic prostate cancer.
    Gartrell BA; Saad F
    Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer and osteoporosis.
    Tuck SP; Hanusch B; Walker J; Datta HK
    Curr Osteoporos Rep; 2013 Mar; 11(1):11-20. PubMed ID: 23355097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab in patients with cancer-a surgical strike against the osteoclast.
    Brown JE; Coleman RE
    Nat Rev Clin Oncol; 2012 Jan; 9(2):110-8. PubMed ID: 22231759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.